Activin A balance regulates epithelial invasiveness and tumorigenesis

Laboratory Investigation

Volumn 94, Issue 10, 2014, Pages 1134-1146

  Le Bras, Grégoire F ^a   Loomans, Holli A ^b   Taylor, Chase J ^a   Revetta, Frank L ^a,c,d   Andl, Claudia D ^a,b,c,d  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VANDERBILT INGRAM CANCER CENTER   (United States)

^d Vanderbilt Digestive Disease Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN A; FOLLISTATIN; MATRIX METALLOPROTEINASE; NEUTRALIZING ANTIBODY; SHORT HAIRPIN RNA; SMAD2 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; UVOMORULIN; ACTIVIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENESIS; CELL INVASION; CELL PROLIFERATION ASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIUM CELL; ESOPHAGUS; ESOPHAGUS CANCER; FIBROBLAST; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING; KERATINOCYTE; LENTIVIRUS INFECTION; MICROENVIRONMENT; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR SPHEROID; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; CARCINOMA, SQUAMOUS CELL; CELL CULTURE; ESOPHAGEAL NEOPLASMS; FEMALE; HOMEOSTASIS; NONOBESE DIABETIC MOUSE; PHYSIOLOGY; SCID MOUSE; TUMOR INVASION; UMBILICAL VEIN ENDOTHELIAL CELL;

ACTIVINS; ANIMALS; CARCINOGENESIS; CARCINOMA, SQUAMOUS CELL; CELLS, CULTURED; ESOPHAGEAL NEOPLASMS; FEMALE; FIBROBLASTS; HOMEOSTASIS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MATRIX METALLOPROTEINASES; MICE, INBRED NOD; MICE, SCID; NEOPLASM INVASIVENESS;

EID: 84921737878     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2014.97     Document Type: Article

References (57)

1. Larsson J, Karlsson S. The role of Smad signaling in hematopoiesis. Oncogene 2005;24:5676-5692.
2. Thisse B, Wright CV, Thisse C. Activin-and nodal-related factors control antero-posterior patterning of the zebrafish embryo. Nature 2000;403:425-428.
3. Wildi S, Kleeff J, Maruyama H, et al. Overexpression of activin A in stage IV colorectal cancer. Gut 2001;49:409-417.
4. Harrison CA, Gray PC, Fischer WH, et al. An activin mutant with disrupted ALK4 binding blocks signaling via type II receptors. J Biol Chem 2004;279:28036-28044.
5. Harrison CA, Wiater E, Gray PC, et al. Modulation of activin and BMP signaling. Mol Cell Endocrinol 2004;225:19-24.
6. Andl CD, Fargnoli BB, Okawa T, et al. Coordinated functions of E-cadherin and transforming growth factor beta receptor II in vitro and in vivo. Cancer Res 2006;66:9878-9885.
7. Ferreira MC, Witz CA, Hammes LS, et al. Activin A increases invasiveness of endometrial cells in an in vitro model of human peritoneum. Mol Hum Reprod 2008;14:301-307.
8. Le Bras GF, Allison GL, Richards NF, et al. CD44 upregulation in E-cadherin-negative esophageal cancers results in cell invasion. PLoS One 2011;6:e27063.
9. Burdette JE, Jeruss JS, Kurley SJ, et al. Activin A mediates growth inhibition and cell cycle arrest through Smads in human breast cancer cells. Cancer Res 2005;65:7968-7975.
10. Danila DC, Inder WJ, Zhang X, et al. Activin effects on neoplastic proliferation of human pituitary tumors. J Clin Endocrinol Metab 2000;85:1009-1015.
11. Reis FM, Luisi S, Carneiro MM, et al. Activin, inhibin and the human breast. Mol Cell Endocrinol 2004;225:77-82.
12. Ho J, de Guise C, Kim C, et al. Activin induces hepatocyte cell growth arrest through induction of the cyclin-dependent kinase inhibitor p15INK4B and Sp1. Cell Signal 2004;16:693-701.
13. Kleeff J, Ishiwata T, Friess H, et al. Concomitant over-expression of activin/inhibin beta subunits and their receptors in human pancreatic cancer. Int J Cancer 1998;77:860-868.
14. Thomas TZ, Wang H, Niclasen P, et al. Expression and localization of activin subunits and Follistatins in tissues from men with high grade prostate cancer. J Clin Endocrinol Metab 1997;82:3851-3858.
15. Woodruff TK. Role of inhibins and activins in ovarian cancer. Cancer Treat Res 2002;107:293-302.
16. Yoshinaga K, Yamashita K, Mimori K, et al. Activin a causes cancer cell aggressiveness in esophageal squamous cell carcinoma cells. Ann Surg Oncol 2008;15:96-103.
17. Rahimi RA, Leof EB. TGF-beta signaling: a tale of two responses. J Cell Biochem 2007;102:593-608.
18. Roberts AB, Wakefield LM. The two faces of transforming growth factor beta in carcinogenesis. Proc Natl Acad Sci USA 2003;100: 8621-8623.
19. Xiao L, Yuan X, Sharkis SJ. Activin A maintains self-renewal and regulates fibroblast growth factor, Wnt, and bone morphogenic protein pathways in human embryonic stem cells. Stem Cells 2006; 24:1476-1486.
20. Katoh M. Network of WNT and other regulatory signaling cascades in pluripotent stem cells and cancer stem cells. Curr Pharm Biotechnol 2011;12:160-170.
21. Lewis MT. The more things changey. The more things change: developmental plasticity of tumor-initiating mammary epithelial cells. Breast Cancer Res 2010;12:101.
22. Kowanetz M, Valcourt U, Bergstrom R, et al. Id2 and Id3 define the potency of cell proliferation and differentiation responses to transforming growth factor beta and bone morphogenetic protein. Mol Cell Biol 2004;24:4241-4254.
23. Rotzer D, Krampert M, Sulyok S, et al. Id proteins: novel targets of activin action, which regulate epidermal homeostasis. Oncogene 2006;25:2070-2081.
24. Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 2002;30:207-210.
25. Kupershmidt I, Su QJ, Grewal A, et al. Ontology-based meta-analysis of global collections of high-throughput public data. PLoS One 2010;29:e13066.
26. Lee JJ, Natsuizaka M, Ohashi S, et al. Hypoxia activates the cyclooxy-genase-2-prostaglandin E synthase axis. Carcinogenesis 2010;31: 427-434.
27. Su H, Hu N, Yang HH, et al. Global gene expression profiling and validation in esophageal squamous cell carcinoma and its association with clinical phenotypes. Clin Cancer Res 2011;17: 2955-2966.
28. Eijken M, Swagemakers S, Koedam M, et al. The activin A-Follistatin system: potent regulator of human extracellular matrix mineralization. FASEB J 2007;21:2949-2960.
29. Symes K, Yordán C, Mercola M. Morphological differences in Xenopus embryonic mesodermal cells are specified as an early response to distinct threshold concentrations of activin. Development 1994;120: 2339-2346.
30. Green JB, Smith JC. Graded changes in dose of a Xenopus activin A homologue elicit stepwise transitions in embryonic cell fate. Nature 1990;347:391-394.
31. Green JB, New HV, Smith JC. Responses of embryonic Xenopus cells to activin and FGF are separated by multiple dose thresholds and correspond to distinct axes of the mesoderm. Cell 1992;71: 731-739.
32. Fuchs E, Horsley V. More than one way to skin. Genes Dev 2008;22: 976-985.
33. Seery JP. Stem cells of the oesophageal epithelium. J Cell Sci 2002;115:1783-1789.
34. Squier CA, Kremer MJ. Biology of oral mucosa and esophagus. J Natl Cancer Inst Monogr 2001;29:7-15.
35. Siegel R, Ma J, Zou Z, et al. Cancer statistics 2014. Cancer J Clin 2014;64:9-29.
36. Yoshinaga K, Mimori K, Yamashita K, et al. Clinical significance of the expression of activin A in esophageal carcinoma. Int J Oncol 2003;22:75-80.
37. Yoshinaga K, Inoue H, Utsunomiya T, et al. N-cadherin is regulated by activin A and associated with tumor aggressiveness in esophageal carcinoma. Clin Cancer Res 2004;10:5702-5707.
38. Yoshinaga K, Mimori K, Inoue H, et al. Activin A enhances MMP-7 activity via the transcription factor AP-1 in an eso-phageal squamous cell carcinoma cell line. Int J Oncol 2008;33: 453-459.
39. Sanford LP, Ormsby I, Gittenberger-de Groot AC, et al. TGFbeta2 knockout mice have multiple developmental defects that are non-overlapping with other TGFbeta knockout phenotypes. Development 1997;124:2659-2670.
40. Hempen PM, Zhang L, Bansal RK, et al. Evidence of selection for clones having genetic inactivation of the activin A type II receptor (ACVR2) gene in gastrointestinal cancers. Cancer Res 2003;63: 994-999.
41. Su GH, Bansal R, Murphy KM, et al. ACVR1B (ALK4, activin receptor type 1B) gene mutations in pancreatic carcinoma. Proc Natl Acad Sci USA 2001;98:3254-3257.
42. Kodach LL, Wiercinska E, de Miranda NF, et al. The bone morphogenetic protein pathway is inactivated in the majority of sporadic colorectal cancers. Gastroenterology 2008;134:1332-1341.
43. Sekiya T, Adachi S, Kohu K, et al. Identification of BMP and activin membrane-bound inhibitor (BAMBI), an inhibitor of transforming growth factor-beta signaling, as a target of the beta-catenin pathway in colorectal tumor cells. J Biol Chem 2004;279:6840-6846.
44. Fritzmann J, Morkel M, Besser D, et al. A colorectal cancer expression profile that includes transforming growth factor beta inhibitor BAMBI predicts metastatic potential. Gastroenterology 2009;137:165-175.
45. Tisdale MJ. Mechanisms of cancer cachexia. Physiol Rev 2009;330: 171-179.
46. Massague J. TGFbeta in Cancer. Cell 2008;134:215-230.
47. Ren P, Chen FF, Liu HY, et al. High serum levels of Follistatin in patients with ovarian cancer. J Int Med Res 2012;40:877-886.
48. Tumminello FM, Badalamenti G, Fulfaro F, et al. Serum Follistatin in patients with prostate cancer metastatic to the bone. Clin Exp Metastasis 2010;27:549-555.
49. Chang KP, Kao HK, Liang Y, et al. Overexpression of activin A in oral squamous cell carcinoma: association with poor prognosis and tumor progression. Ann Surg Oncol 2010;17:1945-1956.
50. Chen M, Sinha M, Luxon BA, et al. Integrin alpha6beta4 controls the expression of genes associated with cell motility, invasion, and metastasis, including S100A4/metastasin. J Biol Chem 2009;284:1484-1494.
51. Ogino H, Yano S, Kakiuchi S, et al. Follistatin suppresses the production of experimental multiple-organ metastasis by small cell lung cancer cells in natural killer cell-depleted SCID mice. Clin Cancer Res 2008;14:660-667.
52. Bamberger C, Schärer A, Antsiferova M, et al. Activin controls skin morphogenesis and wound repair predominantly via stromal cells and in a concentration-dependent manner via keratinoctyes. Am J Pathol 2005;167:733-747.
53. Saka Y, Smith JC. A mechanism for the sharp transition of morphogen gradient interpretation in Xenopus. BMC Dev Biol 2007; 7:4.
54. McDowell N, Gurdon JB. Activin as a morphogen in Xenopus mesoderm induction. Semin Cell Dev Biol 1999;10:311-317.
55. Gurdon JB, Harger P, Mitchell A, et al. Activin signalling and response to a morphogen gradient. Nature 1994;371:487-492.
56. Jones CM, Armes N, Smith JC. Signalling by TGF-family members: short-range effects of Xnr-2 and BMP-4 contrast with the long-range effects of activin. Curr. Biol. 1996;6:1468-1475.
57. Crease DJ, Dyson S, Gurdon JB. Cooperation between the activin and Wnt pathways in the spatial control of organizer gene expression. Proc Natl Acad Sci USA 1998;95:4398-4403.